Literature DB >> 29026923

Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.

Gregory Q Del Prete1, Jeffrey D Lifson2.   

Abstract

Nonhuman primate (NHP) models of AIDS represent a potentially powerful component of the effort to understand in vivo sources of AIDS virus that persist in the setting of suppressive combination antiretroviral therapy (cART) and to develop and evaluate novel strategies for more definitive treatment of HIV infection (i.e., viral eradication "cure", or sustained off-cART remission). Multiple different NHP models are available, each characterized by a particular NHP species, infecting virus, and cART regimen, and each with a distinct capacity to recapitulate different aspects of HIV infection. Given these different biological characteristics, and their associated strengths and limitations, different models may be preferred to address different questions pertaining to virus persistence and cure research, or to evaluate different candidate intervention approaches. Recent developments in improved cART regimens for use in NHPs, new viruses, a wider array of sensitive virologic assay approaches, and a better understanding of pathogenesis should allow even greater contributions from NHP models to this important area of HIV research in the future.

Entities:  

Mesh:

Year:  2018        PMID: 29026923     DOI: 10.1007/82_2017_73

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  10 in total

1.  Evaluating the Intactness of Persistent Viral Genomes in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Initiating Antiretroviral Therapy within One Year of Infection.

Authors:  Samuel Long; Christine M Fennessey; Laura Newman; Carolyn Reid; Sean P O'Brien; Yuan Li; Gregory Q Del Prete; Jeffrey D Lifson; Robert J Gorelick; Brandon F Keele
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.

Authors:  Afam A Okoye; Derick D Duell; Yoshinori Fukazawa; Benjamin Varco-Merth; Alejandra Marenco; Hannah Behrens; Morgan Chaunzwa; Andrea N Selseth; Roxanne M Gilbride; Jason Shao; Paul T Edlefsen; Romas Geleziunas; Mykola Pinkevych; Miles P Davenport; Kathleen Busman-Sahay; Michael Nekorchuk; Haesun Park; Jeremy Smedley; Michael K Axthelm; Jacob D Estes; Scott G Hansen; Brandon F Keele; Jeffery D Lifson; Louis J Picker
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

3.  The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.

Authors:  Alexandra M Bender; Francesco R Simonetti; Mithra R Kumar; Emily J Fray; Katherine M Bruner; Andrew E Timmons; Katherine Y Tai; Katharine M Jenike; Annukka A R Antar; Po-Ting Liu; Ya-Chi Ho; Dana N Raugi; Moussa Seydi; Geoffrey S Gottlieb; Afam A Okoye; Gregory Q Del Prete; Louis J Picker; Joseph L Mankowski; Jeffrey D Lifson; Janet D Siliciano; Greg M Laird; Dan H Barouch; Janice E Clements; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2019-07-10       Impact factor: 31.316

4.  Single-Cell Profiling of Latently SIV-Infected CD4+ T Cells Directly Ex Vivo to Reveal Host Factors Supporting Reservoir Persistence.

Authors:  Andrey Tokarev; Kawthar Machmach; Matthew Creegan; Dohoon Kim; Michael A Eller; Diane L Bolton
Journal:  Microbiol Spectr       Date:  2022-05-05

Review 5.  Advanced model systems and tools for basic and translational human immunology.

Authors:  Lisa E Wagar; Robert M DiFazio; Mark M Davis
Journal:  Genome Med       Date:  2018-09-28       Impact factor: 11.117

6.  Clonal expansion of SIV-infected cells in macaques on antiretroviral therapy is similar to that of HIV-infected cells in humans.

Authors:  Andrea L Ferris; David W Wells; Shuang Guo; Gregory Q Del Prete; Adrienne E Swanstrom; John M Coffin; Xiaolin Wu; Jeffrey D Lifson; Stephen H Hughes
Journal:  PLoS Pathog       Date:  2019-07-10       Impact factor: 6.823

7.  Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies.

Authors:  Michele B Daly; April M Clayton; Susan Ruone; James Mitchell; Chuong Dinh; Angela Holder; Julian Jolly; J Gerardo García-Lerma; James L Weed
Journal:  PLoS One       Date:  2019-11-15       Impact factor: 3.240

8.  Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV.

Authors:  Vickie A Marshall; Nazzarena Labo; Xing-Pei Hao; Benjamin Holdridge; Marshall Thompson; Wendell Miley; Catherine Brands; Vicky Coalter; Rebecca Kiser; Miriam Anver; Yelena Golubeva; Andrew Warner; Elaine S Jaffe; Michael Piatak; Scott W Wong; Claes Ohlen; Rhonda MacAllister; Jeremy Smedley; Claire Deleage; Gregory Q Del Prete; Jeffrey D Lifson; Jacob D Estes; Denise Whitby
Journal:  PLoS Pathog       Date:  2018-07-12       Impact factor: 6.823

9.  African green monkeys avoid SIV disease progression by preventing intestinal dysfunction and maintaining mucosal barrier integrity.

Authors:  Kevin D Raehtz; Fredrik Barrenäs; Cuiling Xu; Kathleen Busman-Sahay; Audrey Valentine; Lynn Law; Dongzhu Ma; Benjamin B Policicchio; Viskam Wijewardana; Egidio Brocca-Cofano; Anita Trichel; Michael Gale; Brandon F Keele; Jacob D Estes; Cristian Apetrei; Ivona Pandrea
Journal:  PLoS Pathog       Date:  2020-03-02       Impact factor: 6.823

10.  Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages.

Authors:  Gerald K Chege; Craig H Adams; Alana T Keyser; Valerie Bekker; Lynn Morris; Francois J Villinger; Anna-Lise Williamson; Rosamund E Chapman
Journal:  Viruses       Date:  2021-03-02       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.